The investigators propose to characterize MPs in aHUS and TTP both at the onset and throughout treatment. The investigators believe that the number, size, and cell origin of MPs will differ between these two diseases. The hypothesis is that endothelial derived MPs will be higher in number and comprise a larger portion of the MP population in aHUS and that platelet MPs will comprise a larger number and greater proportion of MPs in TTP. The investigators believe that MP identity and number can be used to reliably differentiate between aHUS and TTP at disease onset.
Study Type
OBSERVATIONAL
University of Rochester Medical Center
Rochester, New York, United States
Microparticle/Nanoparticle number (an absolute number)
Time frame: an average of 3 months
Microparticle/Nanoparticle size (in nanometers or micrometers)
Time frame: an average of 3 months
Microparticle/Nanoparticle identity (identity of cell type from which they are derived)
Time frame: an average of 3 months
Morbidities
Time frame: 3 months
Mortality
Time frame: 3 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.